About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Innovation Engine New Era Microbiome Therapeutics Discuva Platform Scientific Literature & Publications Investors & Media Investor Center Media Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Summit Presentations Careers
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance September 20, 2015 By CKD Digital
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance September 20, 2015 By CKD Digital